Genmab A (GNMSF) Enterprise Value (2023 - 2025)
Historic Enterprise Value for Genmab A (GNMSF) over the last 3 years, with Q4 2025 value amounting to -$1.7 billion.
- Genmab A's Enterprise Value rose 2257.34% to -$1.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.7 billion, marking a year-over-year increase of 2257.34%. This contributed to the annual value of -$1.7 billion for FY2025, which is 2257.34% up from last year.
- According to the latest figures from Q4 2025, Genmab A's Enterprise Value is -$1.7 billion, which was up 2257.34% from -$1.9 billion recorded in Q3 2025.
- Over the past 5 years, Genmab A's Enterprise Value peaked at -$624.0 million during Q2 2024, and registered a low of -$2.4 billion during Q4 2023.
- In the last 3 years, Genmab A's Enterprise Value had a median value of -$1.7 billion in 2025 and averaged -$1.7 billion.
- Over the last 5 years, Genmab A's Enterprise Value had its largest YoY gain of 2472.31% in 2025, and its largest YoY loss of 12724.36% in 2025.
- Quarter analysis of 3 years shows Genmab A's Enterprise Value stood at -$2.4 billion in 2023, then rose by 7.86% to -$2.2 billion in 2024, then grew by 22.57% to -$1.7 billion in 2025.
- Its last three reported values are -$1.7 billion in Q4 2025, -$1.9 billion for Q3 2025, and -$1.4 billion during Q2 2025.